MK-0966 Protocol 056 - Phase III Dysmenorrhea #2

Analysis of PID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8 and 12 hours on the x-axis is not to scale

		Summary Statistics by Timepoint (Hours Postdose)										
Treatment		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	118	118	118	117	99	89	83	78	72	67	64
	MEAN	0.1 A	0.4 B	0.7 B	0.8 B	1.0 B	1.0 B	1.0 B	0.9 B	0.9 B	0.9 B	0.9 B
	STD	0.4	0.7	0.9	1.0	1.0	1.0	1.1	1.2	1.1	1.1	1.1
MK-0966 25/25 mg	N†	115	115	113	113	107	99	97	94	90	89	84
	MEAN	0.1 A	0.4 AB	0.8 AB	1.1 A	1.3 A	1.4 A	1.4 A	1.4 A	1.3 A	1.2 A	1.1 A
	STD	0.4	0.7	0.8	0.9	0.9	0.9	0.9	1.0	0.9	1.0	1.0
MK-0966 50/25 mg	N†	117	118	118	118	112	103	96	93	92	91	87
	MEAN	0.2 A	0.5 AB	0.8 AB	1.2 A	1.4 A	1.4 A	1.5 A	1.5 A	1.4 A	1.3 A	1.2 A
	STD	0.4	0.7	0.8	0.9	1.0	1.0	1.0	1.0	1.1	1.1	1.1
Naproxen Sodium	N†	122	122	121	121	113	111	106	103	96	92	87
	MEAN	0.2 A	0.6 A	1.0 A	1.3 A	1.5 A	1.5 A	1.5 A	1.4 A	1.4 A	1.3 A	1.1 A
	STD	0.5	0.7	0.9	0.9	0.9	1.0	1.0	1.0	1.1	1.1	1.1
Within Patient Pooled SD		0.4	0.6	0.7	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
Effect		p-Values by Timepoint (Hours Postdose)										
Sequence††		0.755	0.900	0.828	0.597	0.820	0.976	0.969	0.654	0.622	0.576	0.427
Patient(Sequence) ††		0.002	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Period(Square) ††		0.112	0.172	0.359	0.023	0.022	0.344	0.258	0.247	0.136	0.063	0.316
Treatment††		0.339	0.087	0.019	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	0.016
Stratum (Baseline PI) ††		0.006	0.006	0.002	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Carry-over (Residual) ††		0.398	0.092	0.306	0.102	0.521	0.314	0.116	0.222	0.415	0.778	0.747
Rx-by-Stratum Interaction†††		0.501	0.504	0.898	0.887	0.946	0.710	0.328	0.372	0.269	0.235	0.747

†: Observed sample size

††: Model included sequence, patient (sequence), period, treatment, baseline Pain Intensity (PI) as factors.

†††: Model included sequence , patient (sequence), period ,treatment, baseline PI and treatment-by-baseline PI interaction as factors.

A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 056 - Phase III Dysmenorrhea #2

Analysis of PRID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8 and 12 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	118	118	118	117	99	89	83	78	72	67	64
	MEAN	0.5 A	1.3 C	2.1 B	2.5 B	2.7 B	2.8 B	2.7 B	2.5 B	2.5 B	2.5 B	2.4 B
	STD	1.0	1.7	2.2	2.5	2.6	2.6	2.7	2.9	2.8	2.8	2.8
MK-0966 25/25 mg	N†	115	115	113	113	107	99	97	94	90	89	84
	MEAN	0.6 A	1.4 BC	2.4 B	3.1 A	3.8 A	3.9 A	3.9 A	3.9 A	3.8 A	3.5 A	3.0 A
	STD	1.2	1.8	2.1	2.3	2.3	2.4	2.5	2.6	2.5	2.6	2.7
MK-0966 50/25 mg	N†	117	118	118	118	112	103	96	93	92	91	87
	MEAN	0.7 A	1.7 AB	2.5 AB	3.5 A	3.8 A	3.9 A	4.1 A	4.1 A	3.9 A	3.6 A	3.4 A
	STD	1.2	1.8	2.1	2.4	2.4	2.5	2.6	2.6	2.7	2.8	2.8
Naproxen Sodium	N†	122	122	121	121	113	111	106	103	96	92	87
	MEAN	0.7 A	1.9 A	2.9 A	3.6 A	4.1 A	4.2 A	4.1 A	4.0 A	3.8 A	3.7 A	3.2 A
	STD	1.3	1.9	2.1	2.3	2.3	2.4	2.5	2.6	2.8	2.8	2.8
Within Patient Pooled SD		1.1	1.6	1.8	2.1	2.1	2.1	2.2	2.3	2.2	2.2	2.2
Effect		p-Values by Timepoint (Hours Postdose)										
Sequence††		0.318	0.786	0.764	0.612	0.705	0.901	0.924	0.774	0.537	0.552	0.362
Patient(Sequence) ††		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Period(Square) ††		0.110	0.165	0.136	0.026	0.023	0.337	0.318	0.226	0.109	0.073	0.161
Treatment††		0.253	0.010	0.007	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	0.002
Stratum (Baseline PI) ††		0.635	0.678	0.959	0.543	0.685	0.569	0.458	0.428	0.256	0.574	0.272
Carry-over (Residual) ††		0.560	0.175	0.340	0.123	0.511	0.285	0.181	0.191	0.212	0.518	0.736
Rx-by-Stratum Interaction†††		0.741	0.693	0.960	0.976	0.918	0.510	0.433	0.450	0.199	0.339	0.870

†: Observed sample size

††: Model included sequence, patient (sequence), period, treatment, baseline Pain Intensity (PI) as factors.

†††: Model included sequence , patient (sequence), period ,treatment, baseline PI and treatment-by-baseline PI interaction as factors.

A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 072- Phase III Post Orthopedic Surgery Study

Analysis of Pain Relief Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	53	53	45	33	27	21	16	8	8	7	2
	MEAN	0.8 A	1.0 B	1.2 B	1.0 B	1.0 B	0.6 B	0.6 B	0.3 B	0.3 B	0.2 B	0.2 B
	STD	1.0	1.2	1.3	1.3	1.3	1.1	1.1	0.8	1.0	0.7	0.7
MK-0966 50 mg	N†	110	110	97	86	80	68	58	53	46	46	40
	MEAN	0.9 A	1.5 A	1.7 A	1.8 A	1.8 A	1.7 A	1.7 A	1.6 A	1.4 A	1.4 A	1.2 A
	STD	1.0	1.1	1.3	1.5	1.5	1.6	1.7	1.7	1.7	1.7	1.6
Naproxen Sodium	N†	55	55	52	49	44	32	28	27	21	19	14
	MEAN	0.8 A	1.8 A	1.9 A	1.8 A	1.7 A	1.5 A	1.5 A	1.4 A	1.2 A	1.0 A	0.9 A
	STD	1.0	1.1	1.2	1.3	1.5	1.5	1.6	1.6	1.6	1.5	1.6
Pooled SD		1.0	1.1	1.2	1.4	1.4	1.5	1.5	1.5	1.5	1.4	1.4
Effect		p-Values by Timepoint (Hours Postdose)										
Treatment ††		0.902	0.002	0.004	0.001	0.005	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Baseline Pain Intensity (PI) ††		0.232	0.371	0.048	0.019	0.037	0.139	0.153	0.064	0.028	0.134	0.114
Center (Study Site) ††		<0.001	0.150	0.099	0.206	0.056	0.015	0.064	0.152	0.118	0.154	0.129
Surgical Procedure (Surgery) ††		0.419	0.437	0.521	0.993	0.205	0.107	0.120	0.172	0.360	0.263	0.421
Rx-by-Baseline PI Interaction†††		0.969	0.645	0.610	0.866	0.507	0.803	0.771	0.949	0.916	0.933	0.814
Rx-by-Center Interaction†††		0.131	0.608	0.352	0.854	0.264	0.432	0.413	0.881	0.767	0.698	0.714
Rx-by-Surgery Interaction†††		0.166	0.932	0.655	0.080	0.020	0.186	0.118	0.100	0.045	0.187	0.293

†: Observed sample size

††: Model included baseline Pain Intensity (PI), center, surgical procedure, and treatment as factors.

†††: Model included baseline PI, center, surgical procedure, treatment, and the three factor-by-treatment interactions.

A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 072 - Phase III Post Orthopedic Surgery Pain Study
Analysis of PID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	53	53	45	33	27	21	16	8	8	7	2
	MEAN	0.2 A	0.3 B	0.4 B	0.5 B	0.4 B	0.3 B	0.2 B	0.2 B	0.2 B	0.1 B	0.1 B
	STD	0.6	0.8	0.8	0.7	0.7	0.6	0.5	0.5	0.5	0.4	0.4
MK-0966 50 mg	N†	110	110	97	86	80	68	59	52	46	46	40
	MEAN	0.3 A	0.6 A	0.7 A	0.8 A	0.8 A	0.8 A	0.8 A	0.8 A	0.7 A	0.7 A	0.6 A
	STD	0.6	0.7	0.8	0.9	0.9	1.0	0.9	0.9	0.9	0.9	0.9
Naproxen Sodium	N†	55	55	52	49	44	32	28	27	21	19	14
	MEAN	0.2 A	0.6 A	0.8 A	0.8 A	0.7 A	0.6 A	0.7 A	0.5 B	0.5 AB	0.5 A	0.4 A
	STD	0.6	0.7	0.8	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.8
Pooled SD		0.5	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Effect		p-Values by Timepoint (Hours Postdose)										
Treatment ††		0.454	0.042	0.005	0.031	0.030	0.001	<0.001	<0.001	0.001	<0.001	0.002
Baseline Pain Intensity (PI) ††		0.035	0.013	0.010	0.164	0.099	0.079	0.323	0.704	0.698	0.983	0.937
Center (Study Site) ††		<0.001	0.053	0.226	0.271	0.031	0.018	0.107	0.260	0.112	0.128	0.226
Surgical Procedure (Surgery) ††		0.064	0.618	0.043	0.968	0.211	0.035	0.191	0.229	0.278	0.230	0.580
Rx-by-Baseline PI Interaction†††		0.545	0.764	0.120	0.184	0.020	0.487	0.283	0.630	0.816	0.999	0.939
Rx-by-Center Interaction†††		0.625	0.315	0.008	0.803	0.152	0.772	0.532	0.973	0.863	0.846	0.905
Rx-by-Surgery Interaction†††		0.363	0.973	0.153	0.282	0.087	0.071	0.095	0.216	0.120	0.369	0.173

†: Observed sample size
††: Model included baseline Pain Intensity (PI), center, surgical procedure, and treatment as factors.
†††: Model included baseline PI, center, surgical procedure, treatment, and the three factor-by-treatment interactions.
A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 072 - Phase III Post Orthopedic Surgery Pain Study
Analysis of PRID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	53	53	45	33	27	21	16	8	8	7	2
	MEAN	1.0 A	1.3 B	1.5 B	1.5 B	1.4 B	0.9 B	0.8 B	0.5 B	0.5 B	0.3 B	0.2 B
	STD	1.5	1.9	2.0	1.8	1.9	1.5	1.6	1.2	1.4	1.0	1.1
MK-0966 50 mg	N†	110	110	97	86	80	68	58	52	46	46	40
	MEAN	1.2 A	2.1 A	2.4 A	2.6 A	2.6 A	2.5 A	2.5 A	2.4 A	2.1 A	2.1 A	1.8 A
	STD	1.4	1.7	1.9	2.3	2.3	2.5	2.6	2.6	2.5	2.6	2.4
Naproxen Sodium	N†	55	55	52	49	44	32	28	27	21	19	14
	MEAN	1.0 A	2.4 A	2.7 A	2.6 A	2.3 A	2.1 A	2.2 A	1.9 A	1.7 A	1.5 A	1.4 A
	STD	1.5	1.6	1.8	2.1	2.3	2.4	2.5	2.3	2.4	2.3	2.3
Pooled SD		1.4	1.7	1.9	2.1	2.2	2.2	2.3	2.2	2.2	2.2	2.2
Effect		p-Values by Timepoint (Hours Postdose)										
Treatment ††		0.741	0.004	0.003	0.003	0.007	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Baseline Pain Intensity (PI) ††		0.997	0.654	0.782	0.323	0.464	0.760	0.558	0.276	0.183	0.318	0.311
Center (Study Site) ††		<0.001	0.065	0.132	0.194	0.032	0.014	0.075	0.168	0.103	0.138	0.166
Surgical Procedure (Surgery) ††		0.195	0.472	0.220	0.983	0.190	0.065	0.131	0.178	0.315	0.243	0.468
Rx-by-Baseline PI Interaction†††		0.842	0.663	0.347	0.564	0.186	0.678	0.572	0.966	0.993	0.968	0.922
Rx-by-Center Interaction†††		0.266	0.480	0.100	0.830	0.217	0.599	0.452	0.935	0.794	0.765	0.809
Rx-by-Surgery Interaction†††		0.174	0.987	0.470	0.125	0.028	0.122	0.097	0.130	0.059	0.257	0.241

†: Observed sample size
††: Model included baseline Pain Intensity (PI), center, surgical procedure, and treatment as factors.
†††: Model included baseline PI, center, surgical procedure, treatment, and the three factor-by-treatment interactions.
A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

Appendix 4.1.18

Analysis of Total Pain Relief Score Over 8 Hours (TOPAR8)
Unadjusted for Carryover effect

(Intention-to-Treat Approach)

Treatment	N	Mean	SD	LSMean	95% CI for LSMean
Placebo	60	11.4	8.9	10.8	(8.6, 13.0)
MK-0966 50/25 mg	60	18.4	9.8	18.3	(16.0, 20.5)
Naproxen Sodium	59	20.3	8.7	20.1	(17.8, 22.4)

Pairwise Comparison	Difference in LSMeans	95% CI for Difference	p-Value
MK-0966 50/25 mg vs Placebo	7.5	(4.4, 10.6)	<0.001
Naproxen Sodium vs Placebo	9.3	(6.2, 12.4)	<0.001
Naproxen Sodium vs 50/25 mg	1.8	(-1.3, 4.9)	0.254

Effect	p-Value	Pooled Intra-Patient SD
Sequence	0.728	8.3
Patient(Sequence)	0.029	
Period(Square)	0.078	
Treatment	<0.001	
Stratum (ie, Baseline PI)	0.885	

Appendix 4.1.19

Mean Total Pain Relief Score Over 8 Hours (TOPAR8)
by Sequence and for Each period

Sequence	Period 1	Period 2	Period 3	Treatments
1•	15.2	22.7	15.3	Placebo/50 mg/Naproxen
2	22.7	18.2	9.8	50 mg/Naproxen/ Placebo
3	22.0	14.7	19.1	Naproxen/Placebo/50 mg
4	10.9	22.9	15.6	Placebo/Naproxen/50 mg
5	15.6	17.0	8.6	Naproxen/50 mg/ Placebo
6	14.5	9.6	20.5	50 mg/Placebo/Naproxen

•: Evidence of treatment-by-period interaction, which, since it is partially confounded with carryover effect, manifests itself as significant carryover effect. Placebo is similar to naproxen Sodium in Sequence 1, but smaller than MK-0966 50 mg and Naproxen Sodium in every other sequence.

Estimates of carryover effect

carryover	LSmean	p-value
placebo	3.6	0.009
MK-0966 50 mg	-2.7	0.045
Naproxen Sodium	-0.9	0.478

Appendix 4.1.20

Analysis of Sum of Pain Intensity Difference to 8 Hours (SPID8)
Unadjusted for Carryover Effect

(Intention-to-Treat Approach)

Treatment	N	Mean	SD	LSMean	95% CI for LSMean
Placebo	60	5.5	6.6	5.9	(4.4, 7.4)
MK-0966 50/25 mg	60	10.3	6.8	10.7	(9.2, 12.2)
Naproxen Sodium	59	10.8	6.3	11.6	(10.1, 13.2)

Pairwise Comparison	Difference in LSMeans	95% CI for Difference	p-Value
MK-0966 50/25 mg vs Placebo	4.9	(2.8, 6.9)	<0.001
Naproxen Sodium vs Placebo	5.8	(3.7, 7.8)	<0.001
Naproxen Sodium vs 50/25 mg	0.9	(-1.1, 3.0)	0.386

Effect	p-Value	Pooled Intra-Patient SD
Sequence	0.867	5.5
Patient(Sequence)	0.003	
Period(Square)	0.047	
Treatment	<0.001	
Stratum (ie, Baseline PI)	<0.001	

APPEARS THIS WAY
ON ORIGINAL

Appendix 4.1.21

Mean Score of Sum of Pain Intensity Difference to 8 Hours (SPID8)
by Sequence and for Each Period

Sequence	Period 1	Period 2	Period 3	Treatments
1•	7.9	11.1	6.5	Placebo/50 mg/Naproxen
2	12.5	9.1	3.2	50 mg/Naproxen/ Placebo
3	12.8	6.8	11.1	Naproxen/Placebo/50 mg
4	7.5	10.8	9.6	Placebo/Naproxen/50 mg
5	11.4	9.0	3.4	Naproxen/50 mg/ Placebo
6	8.6	4.0	12.7	50 mg/Placebo/Naproxen

•: Evidence of treatment-by-period interaction, which, since it is partially confounded with carryover effect, manifests itself as significant carryover effect. Placebo is similar to naproxen Sodium in Sequence 1, and similar to MK-0966 50 mg in Sequence 4, but smaller than MK-0966 50 mg and Naproxen Sodium in every other sequence.

Estimates of carryover effect

carryover	LSmean	p-value
placebo	2.5	0.006
MK-0966 50 mg	-1.9	0.037
Naproxen Sodium	-0.8	0.443

Appendix 4.1.22

Analysis of Patient's Global Evaluation at 8 Hours
Unadjusted for Carryover Effect

(Intention-to-Treat Approach)

Treatment	N	Mean	SD	LSMean	95% CI for LSMean
Placebo	57	0.9	1.1	1.0	(0.6, 1.3)
MK-0966 50/25 mg	56	1.9	1.4	1.9	(1.5, 2.2)
Naproxen Sodium	58	2.3	1.3	2.3	(2.0, 2.7)

Pairwise Comparison	Difference in LSMeans	95% CI for Difference	p-Value
MK-0966 50/25 mg vs Placebo	0.9	(0.5, 1.4)	<0.001
Naproxen Sodium vs Placebo	1.4	(0.9, 1.8)	<0.001
Naproxen Sodium vs 50/25 mg	0.4	(-0.0, 0.9)	0.073

Effect	p-Value	Pooled Intra-Patient SD
Sequence	0.526	1.2
Patient(Sequence)	0.165	
Period(Square)	0.176	
Treatment	<0.001	
Stratum (ie, Baseline PI)	0.317	

Appendix 4.1.23

Mean Score of Patient's Global Evaluation at 8 Hours
by Sequence and for Each Period

Sequence	Period 1	Period 2	Period 3	Treatments
1•	1.3	3.3	1.4	Placebo/50 mg/Naproxen
2	2.1	1.7	1.0	50 mg/Naproxen/ Placebo
3	2.8	1.0	2.3	Naproxen/Placebo/50 mg
4	0.6	3.1	1.2	Placebo/Naproxen/50 mg
5	2.4	1.5	0.8	Naproxen/50 mg/ Placebo
6	1.3	0.9	2.4	50 mg/Placebo/Naproxen

•: Evidence of treatment-by-period interaction, which, since it is partially confounded with carryover effect, manifests itself as significant carryover effect. Placebo is similar to naproxen Sodium in Sequence 1, but smaller than MK-0966 50 mg and Naproxen Sodium in every other sequence.

Estimates of carryover effect

carryover	LSmean	p-value
placebo	0.9	<0.001
MK-0966 50 mg	-0.5	0.005
Naproxen Sodium	-0.4	0.064

MK-0966 Prot. No. 056
Phase III Dysmenorrhea

APPENDIX 4.1

4.1.18: Analysis of Peak Pain Intensity During 8 Hours Postdose — Unadjusted for Carryover Effect (Intention-to-Treat Approach)

Treatment	N	Mean	SD	LSMean	95% CI for LSMean
Placebo	118	1.3	1.0	1.4	(1.2, 1.5)
MK-0966 25/25 mg	115	1.7	0.9	1.8	(1.6, 1.9)
MK-0966 50/25 mg	118	1.7	0.9	1.8	(1.6, 1.9)
Naproxen Sodium	122	1.8	0.8	1.9	(1.8, 2.0)

Pairwise Comparison	Difference in LSMeans	95% CI for Difference	p-Value
MK-0966 vs Placebo:			
MK-0966 25/25 mg vs Placebo	0.4	(0.2, 0.6)	<0.001a
MK-0966 50/25 mg vs Placebo	0.4	(0.2, 0.6)	<0.001a
Between MK-0966 Doses:			
MK-0966 50/25 mg vs 25/25 mg	0.0	(-0.2, 0.2)	0.970
With Naproxen Sodium			
Naproxen Sodium vs Placebo	0.5	(0.3, 0.7)	<0.001
Naproxen Sodium vs 25/25 mg	0.1	(-0.1, 0.3)	0.183
Naproxen Sodium vs 50/25 mg	0.1	(-0.1, 0.3)	0.192

Effect	p-Value	Pooled Intra-Patient SD
Sequence	0.976	0.8
Patient(Sequence)	<0.001	
Period	0.067	
Treatment	<0.001	
Stratum (ie, Baseline PI)	<0.001	

[a] Step-down test procedure vs placebo.

MK-0966 Prot. No. 056
Phase III Dysmenorrhea

APPENDIX 4.1

4.1.19: Peak Pain Intensity During 8 Hours Postdose (PEAKPID8)
Means by Sequence and for Each Period

Sequence	Period 1	Period 2	Period 3	Period 4	Treatments
1	1.4	1.8	1.8	1.7	Placebo/25 mg/50 mg/Naproxen
2	1.8	1.7	1.3	1.8	25 mg/Naproxen/ Placebo/50 mg
3	1.8	1.1	2.2	1.7	50 mg/Placebo/Naproxen/25 mg
4†	1.8	1.4	1.7	1.6	Naproxen/50 mg/25 mg/Placebo

† Evidence of treatment-by-period interaction, which, since it is partially confounded with carryover effect, manifests itself as significant carryover effect. Placebo is similar to MK-0966 25 mg and naproxen sodium in sequence 4, but is smaller than all the treatments in every other sequence.

Estimates of Carryover Effect

Carryover	Mean	p-Value
Placebo	0.2	0.027
MK-0966 25/25 mg	0.1	0.240
MK-0966 50/25 mg	-0.1	0.110
Naproxen sodium	-0.1	0.076